New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...

GlobalData is betting on approval of lecanemab and the lifting of reimbursement restrictions, with a prediction of $2.76 billion in sales of the drug in the top eight pharma markets (US, France ...

Its cost-effectiveness deliberations for lecanemab arrive at a price range of between $8,500 and $20,600 for a year's treatment, which is well below the $28,000 per year Biogen set for Aduhelm ...

As part of the SC-AI 360 mg weekly maintenance regimen ... Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...

In January 2025, as part of its decision-making process, the EC asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in ...

Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's ...